Dallas, TX: ReportsandReports announce it will carry Takeda Pharmaceutical Co. Ltd: PharmaVitae Profile Market Research Report in its Store.
Browse complete Takeda Pharmaceutical Co. Ltd: PharmaVitae Profile Report
Introduction
This analysis examines the historical and forecast performance for Takeda in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Reasons to Purchase
- Benchmark Takeda’s performance against key rivals in the prescription pharmaceutical sector
- Discover if Takeda will overcome generic competition facing its biggest selling medications
- Investigate the diverse strategies being employed by Japan’s oldest and largest pharmaceutical player
Table of Content
ABOUT DATAMONITOR HEALTHCARE
About the PharmaVitae team
Chapter 1 About this profile
PharmaVitae Explorer database
Chapter structure
Executive summary
Quarterly news update
Company introduction
Company sales
Company financials
Key products and competitors
Data sourcing
Sales data
Analyst consensus
Chapter 2 Executive summary
Key findings
Financial performance, 2002-14
Takeda: PharmaVitae forecasts at a glance
Strategic insight
Prospect of blockbuster genericization prompts wave of pipeline investment
Over 80% of current ethical sales will soon be exposed to generic competition
Additional challenge set to arise from reforms to Japan healthcare system
Capitalization helps to steer long-term strategy and innovation
Follow-on therapies vital in limiting impact of generic penetration
Takeda looks to Kapidex in order to maintain GERD presence
Alogliptin launch delayed after FDA requests additional safety trial data
SWOT analysis
Strengths
Weaknesses
Opportunities
Threats
Table of Contents
Table of figures
Chapter 3 Quarterly news update
Latest prescription pharma product news
Q1 2010
Latest corporate news
Q1 2010
Future product milestones
Chapter 4 Company introduction
Key findings
Background
Key corporate developments
Out-licensing and TAP joint venture provide initial framework for US penetration
Japanese healthcare reforms heighten competition in domestic market
Consumer health
Joint ventures
M&A history
Acquisition of Millennium Pharmaceuticals
Acquisition of Paradigm Therapeutics
Acquisition of Syrrx
M&A strategy
Chapter 5 Company sales
Key findings
Prescription pharmaceutical sales and growth rate analysis, 2002-14
Product analysis
Product analysis, 2002-08
Product analysis, 2008-14
Growth drivers
Growth resistors
Therapy area analysis
Geographic analysis
Launch/core/expiry analysis
Explanation of launch/core/expiry analysis
Launch analysis, 2008-14
Core analysis, 2008-14
Expiry analysis, 2008-14
Launch/core/expiry configuration, 2008-14
Molecule type analysis
Externalization analysis
Chapter 6 Company financials
Key findings
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002-08
Operating costs and profit analysis
Operating costs and profit analysis, 2002-08
Operating cost ratio and profit margin analysis, 2002-08
Operating cost ratio and profit margin analysis, 2008-14
Operating costs and profit analysis, 2008-14
Chapter 7 Key products and competitors
Key findings
Overview
Gastroenterology
Kapidex
Overview
Sales forecast
Takeda goes it alone with Prevacid follow-on
Major competitive threat from generics
Takepron/Prevacid
Overview
Sales forecast
Second-generation PPI sees considerable sales under TAP alliance
OTC Prevacid set to launch following US patent expiry
Prevacid sales slow as uptake of generic omeprazole continues to rise
US exclusivity lost following November 2009 patent expiry
Amitiza
Overview
Sales forecast
New bowel disorder therapy launched in 2006 under license from Sucampo
Impressive early uptake in the US driven by strong clinical evidence
Indication broadening set to enhance venture further
Cardiovascular
Blopress/Blopress Comp
Overview
Sales forecast
Blockbuster ARB franchise with Japanese patent extension out to 2016
Antihypertensive market overview
Genericization of ARB class will erode Blopress market share
Endocrine, metabolic and genetic disorders
Actos/ACTOplus Met
Overview
Sales forecast
Blockbuster antidiabetic gains market-leading status after demise of competitor
Overview of TZD therapeutic use
Further new launches in place to help safeguard against generic Actos
Further growth in Actos franchise sales expected out to patent expiry
Alogliptin franchise
Overview
Sales forecast
SYR-322 is seen as Takeda’s long-term replacement for Actos in the diabetes market
Alogliptin approval delayed by lack of data pertaining to cardiovascular risks
Type 2 diabetes market potential set for further expansion
Actos/alogliptin combination should add significant value to diabetes franchise
Oncology
Lupron Depot
Overview
Sales forecast
LHRH agonist gives Takeda market-leading presence in hormonal therapeutic intervention
Reformulations help Takeda build successful defense against generic leuprolide
Velcade
Overview
Sales forecast
Acquisition of Millennium equips Takeda with enhanced oncology focus
Velcade is the market-leading treatment for relapsed or refractory multiple myeloma
Label extension boosts uptake following initial approval in third-line setting
Velcade in direct competition with Revlimid
Immunology & inflammation
Enbrel
Overview
Sales forecast
Takeda’s biologic presence boosted by Japanese rights to gold standard TNF inhibitor
Chapter 8 Appendix
R&D pipeline
References
Abbreviations
Exchange rates
About Datamonitor
About Datamonitor Healthcare
Datamonitor consulting
Disclaimer
Browse complete Takeda Pharmaceutical Co. Ltd: PharmaVitae Profile Report
Browse all Healthcare Market Research Reports
Browse all Datamonitor Market Research Reports RSS
Browse all Latest Report
Related Reports:
Chugai Pharmaceutical Co. Ltd: PharmaVitae Profile
Daiichi Sankyo Co., Ltd: PharmaVitae Profile
Eisai Co. Ltd: PharmaVitae Profile
About Us:
Reports and Reports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.
Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
Website: http://www.reportsandreports.com/
Blog: http://reportsnreports.wordpress.com/
Blog: http://reportsandreports.blogspot.com/
